KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Intangibles (2017 - 2025)

Amneal Pharmaceuticals has reported Intangibles over the past 9 years, most recently at $563.5 million for Q4 2025.

  • Quarterly results put Intangibles at $563.5 million for Q4 2025, down 23.06% from a year ago — trailing twelve months through Dec 2025 was $563.5 million (down 23.06% YoY), and the annual figure for FY2025 was $563.5 million, down 23.06%.
  • Intangibles for Q4 2025 was $563.5 million at Amneal Pharmaceuticals, down from $587.9 million in the prior quarter.
  • Over the last five years, Intangibles for AMRX hit a ceiling of $1.3 billion in Q2 2021 and a floor of $563.5 million in Q4 2025.
  • Median Intangibles over the past 5 years was $999.0 million (2023), compared with a mean of $962.5 million.
  • Biggest five-year swings in Intangibles: soared 231.48% in 2021 and later decreased 24.64% in 2025.
  • Amneal Pharmaceuticals' Intangibles stood at $1.2 billion in 2021, then decreased by 6.07% to $1.1 billion in 2022, then fell by 18.76% to $890.4 million in 2023, then fell by 17.75% to $732.4 million in 2024, then decreased by 23.06% to $563.5 million in 2025.
  • The last three reported values for Intangibles were $563.5 million (Q4 2025), $587.9 million (Q3 2025), and $649.5 million (Q2 2025) per Business Quant data.